ASCENDIS PHARMA BONE DISEASES A/S: Financial statements 2024
CVR: 32323596
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
ASCENDIS PHARMA BONE DISEASES A/S (CVR 32323596) has filed annual accounts for 2024. In 2024, the company reported a gross profit of EUR -34,018 and a net result of EUR -139,088 compared with EUR -118,956,906 the year before. Equity in the 2024 report amounted to EUR -507,165.
- Gross Profit
- EUR -34,018
- Profit/Loss
- EUR -139,088
- Equity
- EUR -507,165
- Total Assets
- EUR 15,431
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -34K EUR | -139K EUR | -507K EUR | 0 |
| 2023 | - | -112.3M EUR | -119M EUR | -368.1M EUR | 0 |
| 2022 | - | -66.6M EUR | -72.2M EUR | -249.2M EUR | 0 |
| 2021 | - | -58M EUR | -61.8M EUR | -177M EUR | 0 |
| 2020 | - | -38.8M EUR | -41.3M EUR | -115.1M EUR | 0 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
ASCENDIS PHARMA BONE DISEASES A/S has published its annual report for 2023. Gross profit came to DKK -112,332,138, and the net result was DKK -118,956,906.
About ASCENDIS PHARMA BONE DISEASES A/S
ASCENDIS PHARMA BONE DISEASES A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA OSTEOARTHRITIS DIVISION A/S and ASCENDIS PHARMA RHEUMATOLOGY DIVISION A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 229,581,000 and a net result of EUR 134,982,000 compared with EUR -139,088 the year before. Equity in the 2025 report amounted to EUR -372,183,000.